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OBJECTIVE — Zinc transporter 8 (ZnT8) is an islet -cell secretory granule membrane
protein recently identiﬁed as an autoantibody antigen in type 1 diabetes. The aim of this study
wastodeterminetheprevalenceandroleofantibodiestoZnT8(ZnT8As)inadult-onsetdiabetes.
RESEARCH DESIGN AND METHODS — ZnT8As were measured by a radioimmuno-
precipitation assay using recombinant ZnT8 COOH-terminal or NH2-terminal proteins in 193
patients with adult-onset autoimmune diabetes having antibodies to either GAD (GADAs) or
IA-2(IA-2As)andin1,056antibody-negativepatientswithtype2diabetesfromtheNonInsulin
Requiring Autoimmune Diabetes (NIRAD) study.
RESULTS — ZnT8As-COOH were detected in 18.6% patients with autoimmune diabetes and
1.4% with type 2 diabetes. ZnT8As-NH2were rare. ZnT8As were associated with younger age and a
high GADA titer. The use of GADAs, IA-2As, and ZnT8As in combination allowed a stratiﬁcation of
clinical phenotype, with younger age of onset of diabetes and characteristics of more severe insulin
deﬁciency(higherfastingglucoseandA1C,lowerBMI,totalcholesterol,andtriglycerides)inpatients
with all three markers, with progressive attenuation in patients with two, one, and no antibodies (all
Ptrend  0.001). Autoantibody titers, association with high-risk HLA genotypes, and prevalence of
thyroid peroxidase antibodies followed the same trend (all P  0.001).
CONCLUSIONS — ZnT8As are detectable in a proportion of patients with adult-onset au-
toimmune diabetes and seem to be a valuable marker to differentiate clinical phenotypes.
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Z
inctransporter8(ZnT8)isapancre-
atic -cell secretory granule mem-
brane protein that has been recently
identiﬁedasatargetofhumoralimmunity
in type 1 diabetes (1). Autoantibodies to
ZnT8 (ZnT8As) constitute an additional
marker of autoimmune diabetes, which
complementtheestablishedantibodiesto
insulin(IAAs)(2),GAD(GADAs)(3),and
protein tyrosine IA-2 (IA-2As) (4). In the
ﬁrstreport,ZnT8Asweredetectedin63%
ofyoungpatientsatonsetofdisease,over-
lapping with, but also independent of,
GADAs, IAAs, and IA-2As, and the com-
bined use of these four antibody markers
raised the detection rate of autoimmunity
to 94% in new-onset cases of type 1 dia-
betes. Moreover, ZnT8As could be de-
tected also in the preclinical phase of type
1 diabetes, showing a trend to a later ap-
pearancerelativetoIAAs,GADAs,andIA-
2As but with the ability to identify
individualswithamorerapidprogression
to clinical disease. Although islet autoim-
munity is responsible for the large major-
ity of childhood- and adolescent-onset
diabetes,itcanbefoundalsoin4–10%of
adult-onset diabetes. This subgroup of
patientstestpositiveforhumoralmarkers
ofisletautoreactivity,despitehavingclin-
ical features indistinguishable from those
of classic type 2 diabetes, and are charac-
terized as having latent autoimmune dia-
betes of adult (LADA). Patients with
LADA are identiﬁed solely by the detec-
tion of circulating islet autoantibodies,
with islet cell antibodies (ICAs) and
GADAs being the antibody markers with
the highest prevalence (5,6), followed by
IA-2As, which are detected in a minority
of case subjects and are almost invariably
associatedwithGADAs(7),whereasinsu-
lin autoantibodies, which constitute a
speciﬁc marker of juvenile diabetes in-
versely related to age and rare in adults,
areunlikelytobeusefulforLADAscreen-
ing (8–10). The aim of this study was to
evaluate the prevalence of ZnT8As in
adult-onset diabetes and establish their
potential use as an additional marker of
autoimmunity and phenotype character-
ization in this patient population.
RESEARCH DESIGN AND
METHODS— All patients investi-
gated participated in the Non Insulin Re-
quiring Autoimmune Diabetes (NIRAD)
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conducted with the aim of assessing the
prevalence and characteristics of adult-
onset autoimmune diabetes (11). Inclu-
sion criteria were 1) diagnosis of diabetes
accordingtotheAmericanDiabetesAsso-
ciation, with no insulin requirement and
no evidence of ketosis from diagnosis to
screening time, and 2) disease duration
between 6 months and 5 years. Exclusion
criteria included prior insulin therapy,
pregnancy, and the presence of any other
severe disease. The study was approved
by the ethics committees of all participat-
ing centers and written informed consent
was obtained by all patients before
screening. Of the original NIRAD cohort
of 4,250 subjects with adult-onset of ini-
tially non–insulin-requiring diabetes we
studied all 193 patients (4.5% overall
prevalence) with autoimmune diabetes
deﬁnedashavingeitherGADAsorIA-2As
(aged 50.3  12.8 years; mean duration
of diabetes 2.3 years, range 0.6–4.8
years)(11)and1,056patientswithtype2
diabetes (aged 51.8  11.8 years, mean
duration of diabetes 2.4 years, range
0.5–5 years). For the comparison of clin-
ical phenotypes a subset of 348 age- and
sex-matched antibody-negative patients
with type 2 diabetes (aged 51.1  10.8
years; mean duration of diabetes 2.2
years, range 0.5–5 years) was selected.
Previous patient assessment included the
following measurements: anthropomet-
rics; fasting glucose, total cholesterol,
HDL cholesterol, triglycerides, uric acid
and A1C; GADAs, IA-2As, and thyroid
peroxidase (TPO) antibodies; and HLA-
DRB1 and DQB1 typing (11,12). The dis-
tribution of GADA titers in patients with
autoimmunediabeteswasindependentof
diabetes duration and showed a bimodal
distribution. Consistent with this observa-
tion, patients with autoimmune diabetes
were divided into subgroups representing
the two distributions, namely low (32 ar-
bitrary units, equivalent to 300 World
Health Organization units) and high (32
arbitrary units) GADA titers (11,13).
ZnT8 cDNA cloning
Total RNA was extracted from isolated
human pancreatic islets with the Mirvana
kit (Applied Biosystems, Foster City, CA)
according to the total RNA isolation pro-
tocolandreversetranscribedtocDNAus-
ing the SuperScript III First-Strand
Synthesis System for RT-PCR (Invitro-
gen, Carlsbad, CA). The coding regions
of ZnT8 corresponding to amino acids
1–74 (ZnT8-NH2) and amino acids 268–
369 (ZnT8-COOH R325) were ampliﬁed
by PCR using PfuUltra II Fusion HS DNA
Polymerase (Stratagene, La Jolla, CA)
withspeciﬁcprimerscontainingEcoRIre-
striction sites and for the forward primers
anin-framestartcodonwithinthecontext
of a canonical Kozak sequence. Ampliﬁed
PCR products were puriﬁed with Mon-
tage-PCR ﬁlter units (Millipore, Billerica,
MA) and cut with the restriction enzyme
EcoRI (Roche Diagnostics, Basel, Switzer-
land). Digested PCR fragments were pu-
riﬁed with Micropure-EZ spin columns
(Millipore), ligated into the EcoRI site of
the pTnT plasmid vector (Promega, Her-
cules, CA) and transformed by electropo-
ration in TOP10 Escherichia coli bacterial
cells. Plasmid DNA was extracted from
the clones obtained with GenElute spin
columns (Sigma-Aldrich, St. Louis, MO),
and the cDNA insert was veriﬁed by se-
quencing on an ABI3130 automated se-
quencer (Applied Biosystems). For large-
scale plasmid DNA preparations, Qiagen
Midicolumnswereused(Qiagen,Hilden,
Germany). A clone containing a cDNA
encoding for the polymorphic residue
tryptophan in position 325 of ZnT8
(ZnT8-COOH W325) was obtained from
the ZnT8-COOH R325 by site-directed
mutagenesis according to the Quick-
Change protocol (Stratagene).
ZnT8A assay
ZnT8As in patient sera were measured by
immunoprecipitation of radiolabeled re-
combinant ZnT8 antigens. ZnT8 ZnT8-
NH2 and ZnT8-COOH proteins were
expressed in vitro in a rabbit reticulocyte
lysate using the TNT Quick Coupled
Transcription/Translation System SP6 kit
(Promega) in the presence of 40 Ci of
35S-labeled methionine (PerkinElmer,
Waltham,MA),puriﬁedbysize-exclusion
chromatography on NAP-5 columns (GE
Healthcare BioSciences, Uppsala, Swe-
den), and the recovered radioactivity was
measured on a TopCount beta counter
(PerkinElmer). For immunoprecipitation
20,000 cpm of recombinant radiolabeled
ZnT8-NH2, when testing for ZnT8As-
NH2, or a mixture of 10,000 cpm each of
ZnT8-COOH R325 and W325 antigens,
when testing for ZnT8As-COOH, were
addedin25lofTris-bufferedsaline(pH
7.4)-0.1% Tween 20 (TBST) to 2 lo f
human serum for each test sample in du-
plicate wells of a polystyrene 96–deep
well plate (Beckman Coulter, Fullerton,
CA) and incubated overnight at 4°C. Im-
mune complexes were recovered by the
addition of 4 l of resuspended CL4B
protein A–Sepharose (GE Healthcare Bio-
Sciences) in 50 l of TBST and incubated
with agitation at 4°C for 1 h. Protein
A–Sepharosebeadswerethenwashedﬁve
times by adding 750 l of TBST followed
by centrifugation at 700g for 3 min and
bufferremovalbyaspiration.Afterthelast
wash, protein A–Sepharose beads were
resuspended and transferred to the wells
of a 96-well OptiPlate (PerkinElmer),
added with 150 l of MicroScint 40 scin-
tillation ﬂuid (PerkinElmer), and the re-
covered radioactivity was measured by
counting each well for 5 min on a Top-
Count-counter.Resultsareexpressedin
arbitrary units derived by a standard
curvemadeofserialdilutionsofapositive
serum included in each assay run. The
threshold for positivity was placed at the
99th percentile of 100 nondiabetic con-
trol subjects. The assay for ZnT8As-
COOH showed an interassay coefﬁcient
of variation (CV) of 8.4% and an intra-
assay CV of 5.5%, whereas the assay for
ZnT8As-NH2 showed an interassay CV of
9.5% and an intra-assay CV of 6.3%. In
the second international workshop on
ZnT8As held in 2009 by the Diabetes Au-
toantibody Standardization Program, the
assay for ZnT8As-COOH showed a labo-
ratory-reportedsensitivityof68%,aspec-
iﬁcity of 99%, an area under the receiver
operating characteristic curve of 0.8848,
andanadjustedsensitivityof95%andspec-
iﬁcityof74%.TheassayforZnT8As-NH2in
theﬁrstinternationalworkshoponZnT8As
heldin2007showedan11%sensitivityand
99% speciﬁcity.
Statistical analysis
Statistical analysis was performed using
SPSS statistical software (version 13;
SPSS, Chicago, IL). Data are expressed as
frequencies,asmeansSD,orasmedian
(interquartile range). Frequency differ-
ences were compared using the 
2 test
(withtheYatescontinuitycorrection)ora
Fisher exact test when appropriate. The
exploration of statistical differences be-
tween groups for quantitative variables
was investigated using multiple linear re-
gression. Comparisons were adjusted for
age of recruitment, duration of disease,
sex, and therapy. The nonparametric
Mann-Whitney test was used to investi-
gate the relation between TPO titers
(units) and number of antibodies. Data
for triglycerides, HDL, and ZnT8A titers
(units) were transformed using log base
10 to normalize their distributions. HLA
DQB1 and DRB1 allele frequencies were
in Hardy-Weinberg equilibrium (i.e., ob-
Lampasona and Associates
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ciesdidnotdiffersigniﬁcantly).HLAclass
II alleles were evaluated as described pre-
viously (11).
RESULTS
Prevalence of ZnT8As
As reported previously, of the 193 pa-
tients with autoimmune diabetes identi-
ﬁed within the NIRAD study (4.5%
prevalence of adult-onset diabetes), 191
had GADAs and 39 had IA-2As; of these,
154 had GADAs only, 2 had IA-2As only,
and 37 had both (9). ZnT8As-COOH
were detected in 36 of 193 (18.6%) auto-
immune (all 36 with GADAs and 20 with
bothGADAsandIA-2As)and16of1,056
(1.4%) patients with type 2 diabetes (Fig.
1); ZnT8As-NH2 were rare and were
found only in 4 of 193 (2.1%) patients
with autoimmune diabetes (3 also having
ZnT8As-COOH) and 1 of 348 (0.3%) pa-
tients of the subset of matched patients
with type 2 diabetes. Therefore, ZnT8As
hereafter are intended to be ZnT8As-
COOH if not otherwise speciﬁed. The
prevalence of ZnT8As within autoim-
mune patients was higher in younger pa-
tients and declined with age: in subjects
aged0–49years,n22(12.2%);insub-
jects aged 49.1–58.8 years, n  12
(6.6%);andinsubjectsaged58.9years,
n  8 (4.4%) (Ptrend  0.0058). Within
the originally deﬁned autoimmune dia-
betic group, 20 patients were positive for
three autoantibodies, 33 for two autoan-
tibodies (17 with GADAs and IA-2As, 16
with GADAs and ZnT8As), and 140 for
one antibody only (138 with GADAs and
2 with IA-2As) (Fig. 2).
ZnT8As, other autoantibodies, and
clinical phenotype
Withintheoriginalgroupofautoimmune
patients (with either GADAs and/or IA-
2As), those having ZnT8As more fre-
quently had associated high GADA titers
(32 arbitrary units, equivalent to 300
World Health Organization units) (11)
and IA-2As (both P  0.01 vs. ZnT8A-
negative). However, within the group
withhighGADAtiters,nostatisticallysig-
niﬁcant differences in clinical features
were observed between ZnT8A-positive
and -negative patients.
The clinical phenotype analyzed ac-
cording to the number of islet autoanti-
bodies showed a trend toward a younger
age at diagnosis, more prominent fea-
tures of insulin deﬁciency (higher fast-
ing glucose and A1C and lower BMI,
waist circumference, total cholesterol,
triglycerides, and uric acid), and higher
prevalence of associated TPO antibodies
proportional to the number of autoanti-
bodies (all Ptrend  0.001). All of these
traits, although attenuated and with the
exception of total cholesterol and triglyc-
erides, remained signiﬁcantly different in
patients with a single autoantibody com-
pared with those with classic type 2 dia-
betes (all P  0.04). Accordingly, the
titers of GADAs, IA-2As, and ZnT8As and
the prevalence and titers of associated
TPO antibodies, as well as the association
with high-risk HLA genotypes followed
the same trend (all P  0.001) (Table 1).
CONCLUSIONS — This study shows
that ZnT8As, recently identiﬁed as auto-
antibodies associated with juvenile-onset
type 1 diabetes, are also a marker of adult-
onset autoimmune diabetes. Adult diabe-
tes-associated antibodies largely recognized
theCOOHterminaloftheantigen(amino
acids 268–369), whereas antibodies
against the NH2-terminal moiety (amino
acids 1–74) were rare. Therefore, in adult
diabetes ZnT8As essentially correspond
to ZnT8As-COOH. In the cohort of the
NIRAD study, ZnT8As were detected in
18.6%ofpatientspreviouslyidentiﬁedby
GADAs and/or IA-2As; the overall preva-
Figure 1—ZnT8As directed against the COOH domain are more frequent in patients with high-
titer GADA positivity. Filled symbols indicate IA-2A positivity also. Dotted line indicates the
threshold for positivity.
Figure 2—Venn diagram of autoantibody combinations in autoantibody-positive patients with
adult-onset diabetes.
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in younger patients and declining with
age. In the original report, it was shown
that the prevalence of ZnT8As was low in
younger individuals but increased dra-
matically from 3 years onward, peaked at
80% in late adolescence, and tended to
decline thereafter (1). The present ﬁnd-
ings are consistent with the evidence of a
further decrease of ZnT8A prevalence by
increasing age, being observed in 12%
of adult patients 50 years of age and
becoming very rare after age 60. In pa-
tients with adult-onset diabetes previ-
ouslyidentiﬁedasnonautoimmunebased
onGADAandIA-2Ascreening,testingfor
ZnT8As identiﬁed an additional 1.4% of
subjects as autoantibody positive. This
number represents a marginal increase
over the expected 1% of positive subjects
based on the threshold adopted in our
assay and, if extrapolated to the whole
NIRAD cohort, would bring the potential
prevalence of autoantibody-positive sub-
jects with adult-onset diabetes up from
the original 4.5% (11) to 5.9%. It is de-
batable, however, whether positivity for a
single low-titer islet autoantibody other
than GADA is a reliable indicator of auto-
immune disease.
To further extend our analysis, we
correlated the clinical phenotype to the
number of islet autoantibodies, a char-
acteristic that has been demonstrated to
reﬂect the intensity of autoimmune re-
sponse and predict future insulin insufﬁ-
ciency (5,7,10,14). The availability of
ZnT8AsasamarkerinadditiontoGADAs
and IA-2As allowed stratiﬁcation across
the intensity of islet autoimmune re-
sponse, which is clearly reﬂected by the
clinical phenotype of patients with adult
diabetes, with features of more severe in-
sulin insufﬁciency proportional to the
number and, accordingly, titers of islet
autoantibodies. Indeed, when compared
with antibody-negative type 2 diabetes,
patients with multiple antibodies exhib-
ited characteristics more similar to those
of type 1 diabetes, with younger age at
disease onset, higher blood glucose and
A1C, lower BMI, waist circumference,
cholesterol, triglycerides, and uric acid,
andhigherprevalenceofassociatedTPO
antibodies; most of these distinctive
traits, although attenuated, were still
present in patients with a single autoan-
tibody, indicating that even a single
marker of autoimmunity is able to dis-
tinguish a degree of insulin insufﬁ-
ciency more severe than that of classic
type 2 diabetes.
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care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 1, JANUARY 2010 107Unlike GAD and IA-2, ZnT8 is highly
-cell speciﬁc; therefore, the presence of
ZnT8AsinpatientsfromtheNIRADstudy
demonstrates that antigens exclusively
expressed in pancreatic -cells are targets
oftheautoimmuneprocessinadult-onset
diabetes also and supports the usefulness
of ZnT8A measurement in adult patients
already identiﬁed with single GADA pos-
itivity to deﬁne patients with a more se-
vere and islet-speciﬁc autoimmunity.
Insummary,ZnT8Asaredetectedina
signiﬁcant proportion of patients with
adult-onset autoimmune diabetes and
seem to be a valuable marker to differen-
tiate clinical phenotypes within this pa-
tient population.
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